title: What role will 'gliptins' play in glycemic control?
abstract: The gliptins, a new class of oral drugs for type 2 diabietes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levelsof incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.
authors.affiliation: Department of Medicine, Division of Endocrinology, Mount Sinai School of Medicine, New York, NY 10028, USA. zbloomgard@aol.com
authors.forename: Zachary
authors.initials: Z
authors.lastname: Bloomgarden
authors.forename: Andrew
authors.initials: A
authors.lastname: Drexler
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D054795:Incretins
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins